Minocycline /d

Phase 3Small molecule

UUniversity of Florida

Minocycline /d is one of 94 small molecule programs targeting Fragile X Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Fragile X SyndromeActive, not recruiting

Fasting ConditionsCompleted

MinocyclineCompleted

Intracerebral HemorrhageNot yet recruiting

HypertensionRecruiting

Fragile X SyndromePreclinical

Active, not recruiting

Fasting ConditionsPreclinical

Completed

MinocyclinePreclinical

Completed

Intracerebral HemorrhagePhase 3

Not yet recruiting

HypertensionPhase 3

Recruiting

Competition

Competitive Landscape

157 competitors in Hypertension

#DrugCompanyPhaseTrials

Foundayo

Eli Lilly

Phase 3

3 2

Baxfendy

AstraZeneca

Phase 3

3 3

Alka-Seltzer

AAbbott

Phase 3

1 4

Minocycline /d

UUniversity of Florida

Phase 3

1 5

HCP1803-3

Hanmi Pharmaceutical Company Limited

Phase 3

1 6

Avastin

Roche

Preclinical

1 7

Winrevair

Alphagan

Deltavit

HHyundai Pharmaceutical Co., LTD.

Preclinical

2 10

Nipride

EExela Pharma Sciences, LLC.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2028

Post-ApprovalRecruiting

Hypertension

NCT06246396

Q4 2028

Phase 3Not yet recruiting

Intracerebral Hemorrhage

NCT07338175

Clinical

Trials by Indication[1]

Periodontitis2 trials

Effects of AMP Application After Non-surgical Periodontal Therapy on Treatment of Periodontitis

Completed·—·Phase 4·NCT05530252·51 enrolled

Locally Delivered Minocycline in Advanced Periodontitis

Completed·MMahsa University·Phase 4·NCT04076098·40 enrolled

Hypertensive2 trials

Study 2: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

Withdrawn·UUniversity of Florida·Phase 1/2·NCT02133885

Study 1: Effect of Minocycline Treatment on Drug-Resistant Hypertensive Patients

Completed·UUniversity of Florida·Phase 2·NCT02133872·34 enrolled

Hypertension1 trial

Antihypertensive Mechanisms of Minocycline in Resistant Hypertension

Recruiting·UUniversity of Florida·Phase 4·NCT06246396·120 enrolled

Brain Injury1 trial

Multi-Arm Multi-Stage Adaptive Platform Trial (APT) for the Acute Treatment of Traumatic Brain Injury

Enrolling by invitation·UUniversity of California, San Francisco·Phase 2·NCT05826912·672 enrolled

Helicobacter Pylori Eradication1 trial

Effectiveness of Minocycline-Containing Bismuth Quadruple Therapy for Helicobacter Pylori Eradication

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04558502·339 enrolled

9 more indications

Intracerebral Hemorrhage1 trial

Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage

Not yet recruiting·—·Phase 3·NCT07338175·1,192 enrolled

Fragile X Syndrome1 trial

Trial of Minocycline to Treat Children With Fragile X Syndrome

Completed·UUniversity of California, Davis·N/A·NCT01053156·66 enrolled

Breast Cancer1 trial

Minocycline Hydrochloride in Reducing Chemotherapy Induced Depression and Anxiety in Patients With Stage I-III Breast Cancer

Completed·OOhio State University Comprehensive Cancer Center·Phase 2·NCT02203552·56 enrolled

Adult1 trial

Impact of DFD-29 on Microbial Flora of Healthy, Adult Human Subjects When Administered Over 16 Weeks

Completed·UUnknown Sponsor·Phase 1·NCT05597462·60 enrolled

Peripheral Neuropathy1 trial

Minocycline Hydrochloride in Reducing Chemotherapy-Induced Peripheral Neuropathy and Acute Pain in Patients With Breast Cancer Undergoing Treatment With Paclitaxel

Completed·—·Phase 2·NCT02297412·47 enrolled

Ischemic stroke1 trial

Efficacy and Safety of Minocycline in Patients With Moderate to Severe Acute Ischemic Stroke

Completed·—·Phase 3·NCT05836740·1,724 enrolled

Low back pain1 trial

Evaluating the Role of Neuroinflammation in Low Back Pain

Completed·MMarco Loggia·Phase 2·NCT03106740·60 enrolled

Fasting Conditions1 trial

Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fasting Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT02312297·28 enrolled

Minocycline1 trial

Bioequivalence Study of Minocycline HCl 135 mg ER Tablet Sunder Fed Conditions

Completed·RRanbaxy Laboratories Limited·N/A·NCT02312609·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for Minocycline /d. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Minocycline /d compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Minocycline /d. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Florida

Minocycline /d

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2028

Q4 2028

Trials by Indication[1]

Periodontitis2 trials

Hypertensive2 trials

Hypertension1 trial

Brain Injury1 trial

Helicobacter Pylori Eradication1 trial

Intracerebral Hemorrhage1 trial

Fragile X Syndrome1 trial

Breast Cancer1 trial

Adult1 trial

Peripheral Neuropathy1 trial

Ischemic stroke1 trial

Low back pain1 trial

Fasting Conditions1 trial

Minocycline1 trial

References

Drug Info

Quick Facts

Related News